Allergan acquires TopokineTherapeutics and with it XAF 5 for treatment of steatoblepharon

Allergan plc a leading global pharmaceutical company, announced that it has acquired Topokine Therapeutics, a privately held, clinical-stage biotechnology company focused on developing topical medicines for fat reduction. Under the terms of the agreement, Allergan acquired Topokine Therapeutics for an upfront payment of $85 million and success-based development and sales milestones for XAF5 , a first-in-class topical agent in late-stage development for the treatment of steatoblepharon, also known as undereye bags.